Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients - PubMed (original) (raw)

Clinical Trial

Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients

M Azizi et al. J Hypertens. 2000 Aug.

Abstract

Background: Additive hemodynamic effects of combined blockade of the renin-angiotensin system by an angiotensin I converting enzyme inhibitor and an angiotensin II antagonist have been observed in sodium-depleted normotensive volunteers and in patients with congestive heart failure.

Objective: To investigate whether the same additive hemodynamic effects occur in patients with hypertension and to verify the safety of such an approach.

Design: Multicenter, randomized, double-blind, parallel-group, pilot study.

Patients: 177 patients with mild-to-moderate hypertension [diastolic blood pressure (DBP): 95-115 mmHg after a 4-week placebo run-in period] were included in the study.

Intervention: Combination therapy consisting of 50 mg losartan daily and 10 mg enalapril daily was administered for 6 weeks. The effects of this therapeutic regimen was compared with similar groups of patients who received either 50 mg losartan daily or 10 mg enalapril daily.

Main outcome measures: 24-hour ambulatory mean DBP and clinic DBP measured at trough after 6 weeks of treatment.

Results: 24-hour ambulatory mean DBP did not significantly differ between treatment groups although the combination tended to lower BP more. The combination therapy was more effective on clinic DBP measured at trough than was losartan by 3.2 mmHg [confidence interval (95%, CI) 0.7-5.7 mmHg, P = 0.012], and more effective than enalapril by 4.0 mmHg (95% CI, 1.5-6.4 mmHg, P = 0.002). In a subgroup of 28 patients, higher plasma active renin and angiotensin I levels during blockade by the combination therapy were observed. This finding confirmed that the combination of the two agents inhibited the renin-angiotensin system to a greater extent than did either agent alone.

Conclusion: A combination of 10 mg enalapril daily and 50 mg losartan daily safely induces a supplementary, although modest, fall in clinic DBP in patients with mild-to-moderate essential hypertension.

PubMed Disclaimer

Cited by

A systematic review and network meta-analysis of the comparative efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension.
Dimou C, Antza C, Akrivos E, Doundoulakis I, Stabouli S, Haidich AB, Kotsis V. Dimou C, et al. J Hum Hypertens. 2019 Mar;33(3):188-201. doi: 10.1038/s41371-018-0138-y. Epub 2018 Dec 5. J Hum Hypertens. 2019. PMID: 30518809
Sex-specific long-term blood pressure regulation: Modeling and analysis.
Leete J, Layton AT. Leete J, et al. Comput Biol Med. 2019 Jan;104:139-148. doi: 10.1016/j.compbiomed.2018.11.002. Epub 2018 Nov 10. Comput Biol Med. 2019. PMID: 30472496 Free PMC article.
Should ACE inhibitors and ARBs be used in combination in children?
Stotter BR, Ferguson MA. Stotter BR, et al. Pediatr Nephrol. 2019 Sep;34(9):1521-1532. doi: 10.1007/s00467-018-4046-8. Epub 2018 Aug 15. Pediatr Nephrol. 2019. PMID: 30112656 Free PMC article.
Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration.
Alvarenga EC, Fonseca MC, Carvalho CC, Florentino RM, França A, Matias E, Guimarães PB, Batista C, Freire V, Carmona AK, Pesquero JB, de Paula AM, Foureaux G, Leite MF. Alvarenga EC, et al. PLoS One. 2016 Dec 19;11(12):e0165371. doi: 10.1371/journal.pone.0165371. eCollection 2016. PLoS One. 2016. PMID: 27992423 Free PMC article.
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.
Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Makani H, et al. BMJ. 2013 Jan 28;346:f360. doi: 10.1136/bmj.f360. BMJ. 2013. PMID: 23358488 Free PMC article. Review.

Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients - PubMed (original) (raw)